Avalo Therapeutics AVTX PP&E (Net)
PP&E (Net) at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept avtx:PropertyPlantAndEquipmentAndOperatingLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's pp&e (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's PP&E (net)?
- Avalo Therapeutics (AVTX) reported PP&E (net) of $375K in Q1 2026.
- How has Avalo Therapeutics's PP&E (net) changed year-over-year?
- Avalo Therapeutics's PP&E (net) decreased by 60.5% year-over-year, from $949K to $375K.
- What is the long-term trend for Avalo Therapeutics's PP&E (net)?
- Over 5 years (2020 to 2025), Avalo Therapeutics's PP&E (net) has grown at a -22.1% compound annual growth rate (CAGR), from $1.61M to $460K.
- What does PP&E (net) mean?
- This represents the net book value of long-term tangible assets, such as laboratory equipment, facilities, and leasehold improvements, used in the company's research and development operations. It reflects the capital investment in the physical infrastructure necessary to support clinical-stage drug development. Monitoring this balance helps investors assess the company's commitment to internal R&D capabilities versus outsourced manufacturing or research models.